Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting — Sponsor Intelligence | 50 EU Trials

Filter these 50 trials by condition, phase, country and more.

Open in Search →

50 Registered trials

29 Recruiting

15 Completed trials

12 Countries active

84 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase III: 8 Phase II/III: 6 Phase II: 22 Phase I/II: 4 Phase IV: 4 Phase I: 1 Phase I (Other): 4 Phase I (FiH): 1

Oversight events:

5 serious breaches 1 temporary halt 2 corrective measures across 6 trials

View oversight register →

100%

15 of 15 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Colorectal cancer metastatic 2 HER2 positive breast cancer 2 Triple negative breast cancer 1 Breast cancer metastatic 1 EGFR gene mutation 1 Prostate cancer 1 Colorectal cancer 1 Pleural mesothelioma malignant recurrent 1 Clear cell renal cell carcinoma 1

Top IMPs

NIVOLUMAB 10 IPILIMUMAB 8 ATEZOLIZUMAB 5 PEMBROLIZUMAB 5 CAPECITABINE 4 PACLITAXEL 4 BEVACIZUMAB 3 CARBOPLATIN 3 CISPLATIN 3 OLAPARIB 3 OXALIPLATIN 3 3-(4-METHYLPIPERAZINE-1-CARBONYL)-7-OXABICLO[2.2.1]HEPTANE-2-CARBOXYLIC ACID 2

All trials

50 total

DUAL Pending

2023-505453-40-00 Phase I (FiH) 1 country 99MTC-EUK-(SO3)CY5-MAS3
Neoadjuvant AXITINIB plus AVELUMAB for patients with localized RCC and a moderate to high risk of recurrence Pending

2024-515825-27-00 Phase II 1 country AVELUMAB; AXITINIB
Adjuvant Pembrolizumab in patients with early-stage triple negative breast cancer with residual disease after treatment with chemotherapy an… Pending

2025-524229-41-00 Phase III 1 country CAPECITABINE; OLAPARIB; PEMBROLIZUMAB; TEGAFUR, GIMERACIL, OTERACIL
Comparison of standard abiraterone dosing and dosing based on abiraterone blood levels Pending

2025-524440-35-00 Phase IV 1 country ABIRATERONE ACETATE
Multicenter phase 1b/II trial testing neoadjuvant intradermal Ipilimumab and Nivolumab in high risk stage II melanoma –MARIANE Recruiting

2023-505945-19-00 Phase II 3 countries
IMCISION: Towards organ preservation and cure via ultra-short immunotherapy in advanced oral cancer. The IMCISION II trial, an investigator… Recruiting

2025-522500-24-00 Phase III 1 country IPILIMUMAB; NIVOLUMAB
Bevacizumab for the treatment of cerebral RAdiation Induced NecrosiS (BRAINS) study: A multicenter, open-label, randomized clinical trial to… Recruiting

2024-512466-34-00 Phase III 1 country
Contrast-enhanced ultrasound for sentinel node detection in patients with melanoma, breast cancer or head & neck cancer Recruiting

2024-515259-40-00 Phase II/III 1 country PERFLUBUTANE
Towards organ preservation and cure via immunotherapy in cutaneous squamous cell carcinoma patients, normally undergoing morbid curative sur… Recruiting

2024-516152-17-00 Phase II 1 country IPILIMUMAB; NIVOLUMAB
Transtympanic sodium thiosulfate to prevent cisplatin-related hearing loss, a randomized controlled multicenter phase III trial; The SOUND t… Recruiting

2023-503313-30-01 Phase III 1 country
Exploiting the synergistic effect of PARP inhibition with cisplatin and hyperthermia during interval cytoreductive surgery and HIPEC in ovar… Recruiting

2024-519170-39-00 Phase I/II 1 country
Biodistribution Evaluation to Reduce Administered Radiopharmaceutical Dose on LOng Axial Field of VieW PET Scanners – BELOW trial Recruiting

2024-512906-24-00 Phase I (Other) 1 country
Whole body HER3 quantification with radiolabelled Patritumab deruxtecan (HER3-DXd) PET/CT Recruiting

2023-508233-14-00 Phase II 1 country PATRITUMAB DERUXTECAN; ZIRCONIUM (89ZR) PATRITUMAB DERUXTECAN
HiPRESS study Recruiting

2024-513598-33-00 Phase IV 1 country ARGIPRESSIN
A Phase 2 clinical study to assess efficacy of induction carboplatin/paclitaxel + pembrolizumab for locoregionally advanced penile cancer: P… Recruiting

2023-506731-15-00 Phase II 2 countries CARBOPLATIN; PACLITAXEL; PEMBROLIZUMAB
PHASE Ib STUDY WITH THE COMBINATION OF LB–100 (PP2A INHIBITOR) AND ATEZOLIZUMAB (PD–L1 INHIBI-TOR) IN METASTATIC COLORECTAL CANCER PATIENTS … Recruiting

2023-505534-98-00 Phase I 1 country 3-(4-METHYLPIPERAZINE-1-CARBONYL)-7-OXABICLO[2.2.1]HEPTANE-2-CARBOXYLIC ACID; AT…
Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with long-acting Somatostatin Analogues – ATSA trial Recruiting

2023-505884-35-00 Phase IV 1 country
NOvel Immunotherapy strategies for advanced Triple negative breast Cancer (TNBC) patients: TONIC-3 trial Recruiting

2023-507875-23-00 Phase II 1 country ATEZOLIZUMAB; IPILIMUMAB; TIRAGOLUMAB
Basket study for oligo-metastatic breast cancer - ANISE Recruiting

2023-505039-11-00 Phase II 5 countries TRASTUZUMAB DERUXTECAN
A phase 2 trial in stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab - TURANDORELA Recruiting

2023-507460-39-00 Phase II/III 1 country NIVOLUMAB; RELATLIMAB
PEHAB II Recruiting

2023-507466-40-00 Phase IV 1 country PHENTOLAMINE MESILATE, PAPAVERINE HYDROCHLORIDE; SILDENAFIL
Primary chemoradiation versus neoadjuvant chemotherapy followed by surgery as treatment strategy for locally advanced vulvar carcinoma (VULC… Recruiting

2022-502685-25-00 Phase II/III 4 countries
Neoadjuvant trastuzumab, pertuzumab and tucatinib without chemotherapy in HER2-positive breast cancer: the TRAIN-4 study Recruiting

2024-518192-61-00 Phase I/II 1 country PERTUZUMAB; TRASTUZUMAB
Validation of ICG-99mTc-nanoscan as hybrid tracer for sentinel node biopsy Recruiting

2024-519351-28-00 Phase II 1 country

Showing 1–24 of 50 trials

← All sponsors A–Z